You are here

  • Home
  • Archive
  • Volume 11, Issue 5
  • First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

 

Online download statistics by month:

Online download statistics by month: May 2023 to March 2024

AbstractFullPdf
May 202341341573
Jun 202353053583
Jul 202316616662
Aug 202320020053
Sep 202313613647
Oct 202313413528
Nov 202314714845
Dec 202317017150
Jan 20249810164
Feb 2024959640
Mar 202415415494
Total22432257639